Newsletters

2021-03-26T16:12:40-07:00

FDA Continues to Create More Communication Pathways Between Payors and Companies

September 2018
Rowinski Group considers the Federal Food and Drug Administration‘s (FDA) efforts to facilitate communication pathways between medical technology companies and payors relevant because the pathways may offer companies opportunities to begin reimbursement planning for their medical or digital technology well before it is cleared or approved by the FDA.

2021-03-26T16:14:13-07:00

Preliminary Changes to Medicare Reimbursement for Clinicians

December 2016
We believe Medicare’s Quality Payment Program may offer unique opportunities to monetize your medical device, diagnostic test or digital health technology outside of traditional reimbursement pathways.  It takes time to determine the value of incorporating the Quality Payment Program into your product development, clinical trial, and sales efforts.

2021-03-26T16:14:40-07:00

Physician Reimbursement Reforms and New Delivery Models under Medicare

May 2015
We are sending this brief to provide you with practical ideas on how to use reimbursement data and payer decisions and policy to help you adjust your business plans and objectives.  We consider payer policy and data to be a source of high-quality market intelligence because it is timely, actual (not forecasted) and derived from reputable sources.

Home » Newsletter Library